Filtered By:
Specialty: Neurology
Condition: Thrombosis
Drug: Pradaxa
This page shows you your search results in order of date.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis
ConclusionsThe safety and efficacy results of NOAC use for CVT were similar to those for age-matched and sex-matched controls treated with VKAs, as well as historical published controls. Assessment of NOAC efficacy and safety in CVT in multicenter cohort studies and randomized controlled trials is warranted.
Source: Neurocritical Care - May 27, 2021 Category: Neurology Source Type: research
Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity
The plasminogen activator inhibitor-1 (PAI-1) 4G/4G homozygous genotype represents a genetic thrombophilia that has been associated with enhanced risk of arterial and venous thrombotic events. The optimal anticoagulation strategy for PAI-1 4G homozygous patients is unclear. Herein we present a case of a patient with PAI-1 4G/4G homozygosity who was placed on dabigatran after developing cerebral venous sinus thrombosis (CVST), but who then suffered an acute myocardial infarction several weeks later.
Source: Journal of Stroke and Cerebrovascular Diseases - August 25, 2020 Category: Neurology Authors: Daniel Chiu, Jesse Weinberger Tags: Case Report Source Type: research
Safety and Efficacy of Dabigatran vs Warfarin After CVT
This randomized clinical trial conducted in 9 countries compares the use of dabigatran with warfarin in stroke prevention among patients who just experienced cerebral venous thrombosis.
Source: JAMA Neurology - September 3, 2019 Category: Neurology Source Type: research
Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan
Background: Asians with atrial fibrillation carry a higher risk of ischemic stroke than non-Asians even under treatment of nonvitamin K antagonist oral anticoagulants. The purpose of the study was to observe the feasibility of intravenous thrombolytic therapy after administering a reversal agent, idarucizumab, in dabigatran-treated patients with acute ischemic stroke in Taiwan. Methods: Dabigatran-treated patients with acute ischemic stroke who received intravenous recombinant tissue plasminogen activator (rt-PA) after idarucizumab reversal were enrolled in the retrospective nationwide study.
Source: Journal of Stroke and Cerebrovascular Diseases - December 17, 2018 Category: Neurology Authors: Chen-Wen Fang, Yi-Te Tsai, Ping-Chen Chou, Hsi-Ming Chen, Chien-Ming Lu, Chen-Rong Tsao, Chih-Lin Chen, Mu-Chien Sun, Yu-Song Shih, Cheng-Yang Hsieh, Lu-An Chen, Po-Lin Chen, Jung-Tze Yeh, Yi-Heng Li Source Type: research
Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review
Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab.
Source: Journal of Stroke and Cerebrovascular Diseases - March 16, 2018 Category: Neurology Authors: Yuichiro Ohya, Noriko Makihara, Kayo Wakisaka, Takao Morita, Tetsuro Ago, Takanari Kitazono, Hitonori Takaba Tags: Case Studies Source Type: research
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants
ConclusionsIn this expert opinion paper, it is suggested that IVT can be performed in patients selected according to the time elapsed since the drug was last taken, renal function, type of hospital where the patient is admitted and plasma concentration of DOAC.
Source: European Journal of Neurology - March 9, 2018 Category: Neurology Authors: E. Touz é, Y. Gruel, I. Gouin‐Thibault, E. De Maistre, S. Susen, P. Sie, L. Derex Tags: Original Article Source Type: research
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) French Vascular Neurology Society and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT) French study Group on Haemostasis and Thrombosis
ConclusionsIn this expert opinion paper, we suggest that IVT can be performed in patients selected according to the time elapsed since the drug was last taken, renal function, type of hospital where the patient is admitted and plasma concentration of DOAC.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - January 23, 2018 Category: Neurology Authors: Emmanuel Touz é, Yves Gruel, Isabelle Gouin‐Thibault, Emmanuel De Maistre, Sophie Susen, Pierre Sie, Laurent Derex Tags: Original Article Source Type: research
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence
ConclusionExperience with idarucizumab administration prior to tissue plasminogen activator treatment in acute ischemic stroke is limited. Initial clinical experience in less severe stroke syndromes and short time windows seems favorable. Larger cohorts are required to confirm safety, including bleeding complications and the risk of thrombosis.
Source: CNS Drugs - August 14, 2017 Category: Neurology Source Type: research
Thrombocytopenia induced by dabigatran: two case reports
Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke). These ...
Source: BMC Neurology - June 29, 2017 Category: Neurology Authors: Hyun Goo Kang, Seung Jae Lee, Ji Yeon Chung and Jin Sung Cheong Source Type: research
Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)
Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Barazangi, N., Sorensen, S., Chen, C., Wong, C., Yee, A., Ke, M., Rose, J., Grosvenor, D., Bedenk, A., Fernandes, J., Tong, D. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research
Successful Treatment with t-PA of a Stroke Patient after Reversal of Dabigatran with Idarucizumab (P3.291)
Conclusions:We report the first successful treatment with t-PA of an acute stroke patient after reversal of dabigatran with idarucizumab.Disclosure: Dr. Cossey has nothing to disclose. Dr. Reddy has nothing to disclose. Dr. Savitz has received research support from the NIH. Dr. Grotta has received personal compensation for activities with Frazer and Stryker. Dr. Grotta has received research support from Genentech and Medtronic.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cossey, T., Reddy, S., Savitz, S., Grotta, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of stroke/thromboembolism in atrial fibrillation patients. Major bleeding risk was significantly higher with rivaroxaban than with dabigatran, as was all-cause mortality and gastrointestinal bleeding. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in gastrointestinal bleeding and decreased risk of intracranial hemorrhage.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Ying Bai, Hai Deng, Alena Shantsila, Gregory Y.H. Lip Tags: Meta Analysis, Quality and Outcomes Original Contributions Source Type: research
Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs
Atrial fibrillation (AF) is one of the most frequent causes of stroke. Secondary prophylaxis by oral anticoagulants (OACs) is recommended after stroke in patients with AF. For decades, vitamin-K antagonists (VKAs) were the only available drugs for OAC. In the last years, non-vitamin K antagonist oral anticoagulants (NOACs) like dabigatran, rivaroxaban, apixaban or edoxaban have been introduced as OAC drugs for patients with AF or venous thromboembolism, based on large randomized trials, and their use is recommended by various guidelines.
Source: Epilepsy Research - July 7, 2016 Category: Neurology Authors: Claudia St öllberger, Josef Finsterer Tags: Short communication Source Type: research
Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
We describe a 75-year-old female patient with nonvalvular atrial fibrillation who presented with acute ischemic stroke during treatment with dabigatran 2 × 110 mg per day. After informed consent, we reversed the anticoagulant effects of dabigatran using idarucizumab and applied an intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (off-label use). An intracerebral hemorrhage was excluded after systemic thrombolysis. Despite the IVT, the patient’s clinical condition deteriorated and she developed an ischemic lesion in the right pons, the right thalamus and right cerebellum. To date, the literatu...
Source: Case Reports in Neurology - June 27, 2016 Category: Neurology Source Type: research
